Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Serum YKL-40 : a new independent prognostic marker for skeletal complications in patients with multiple myeloma. / Mylin, Anne K; Abildgaard, Niels; Johansen, Julia S; Heickendorff, Lene; Kreiner, Svend; Waage, Anders; Turesson, Ingemar; Gimsing, Peter; Nordic Myeloma Study Group.
In: Leukemia and Lymphoma, Vol. 56, No. 9, 2015, p. 2650-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Serum YKL-40
T2 - a new independent prognostic marker for skeletal complications in patients with multiple myeloma
AU - Mylin, Anne K
AU - Abildgaard, Niels
AU - Johansen, Julia S
AU - Heickendorff, Lene
AU - Kreiner, Svend
AU - Waage, Anders
AU - Turesson, Ingemar
AU - Gimsing, Peter
AU - Nordic Myeloma Study Group
PY - 2015
Y1 - 2015
N2 - In a time of increasing treatment options for multiple myeloma bone disease, risk factors predicting progression need to be elucidated. This study investigated the value of serum YKL-40, previously shown to be associated with radiographic progression of bone destruction, as a predictor for time to clinical progression, i.e. skeletal-related events (SREs), in 230 newly diagnosed patients with multiple myeloma receiving intravenous bisphosphonates. Serum concentrations of YKL-40 and biochemical bone markers (CTX-MMP, CTX-I, PINP) were measured at diagnosis. Patients were evaluated every third month for SRE and at 9 and 24 months for radiographic progression. Elevated serum YKL-40 was seen in 47% of patients and associated with high-risk disease (International Staging System stage III; p < 0.001), increased bone resorption (serum CTX/MMP; p < 0.001) and early radiographic progression at 9 months (p = 0.01). Serum YKL-40 together with serum CTX-MMP/PINP ratio and World Health Organization status were independent predictors of time to first SRE.
AB - In a time of increasing treatment options for multiple myeloma bone disease, risk factors predicting progression need to be elucidated. This study investigated the value of serum YKL-40, previously shown to be associated with radiographic progression of bone destruction, as a predictor for time to clinical progression, i.e. skeletal-related events (SREs), in 230 newly diagnosed patients with multiple myeloma receiving intravenous bisphosphonates. Serum concentrations of YKL-40 and biochemical bone markers (CTX-MMP, CTX-I, PINP) were measured at diagnosis. Patients were evaluated every third month for SRE and at 9 and 24 months for radiographic progression. Elevated serum YKL-40 was seen in 47% of patients and associated with high-risk disease (International Staging System stage III; p < 0.001), increased bone resorption (serum CTX/MMP; p < 0.001) and early radiographic progression at 9 months (p = 0.01). Serum YKL-40 together with serum CTX-MMP/PINP ratio and World Health Organization status were independent predictors of time to first SRE.
U2 - 10.3109/10428194.2015.1004168
DO - 10.3109/10428194.2015.1004168
M3 - Journal article
C2 - 25573204
VL - 56
SP - 2650
EP - 2659
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 9
ER -
ID: 162114766